Making a mesothelioma prognosis is often difficult. The average survival rate for someone who receives a diagnosis of the disease is typically a relatively short period of time due to the amount of progression of the disease that has already taken place. Because mesothelioma symptoms can appear dormant for decades, a proper diagnosis is normally not made until the disease has progressed significantly. However, the prognosis of mesothelioma, or the outlook for recovery, is dependent on factors such as the cancer’s stage, patient health and age, tumor size, and other issues.

Some research suggests that the average rate of survival for mesothelioma cancer patients is one year from their initial diagnosis of having a malignancy. The presence of anemia, chest or abdominal fluid, and other elevating conditions can worsen the prognosis.

There is no cure for mesothelioma, therefore the disease is deemed terminal in patients who are afflicted with it. Surgery and other treatment options are available for helping prolong the lives of patients with the illness, as well as improve the quality of life for patients suffering with advanced symptoms.

Some factors are equated with a better prognosis including cell type and patient’s age. A less favorable prognosis is often found in patients with a fibrosarcomatus cell type, and in older individuals. A more favorable prognosis is seen in patients whose symptoms do not include significant weight loss and evidence of extensive cell damage or disease involvement in certain areas.

It is important for those who exhibit possible symptoms of mesothelioma cancer to seek medical attention and obtain a proper diagnosis of their condition. Mesothelioma is caused by exposure to asbestos, a naturally occurring toxic mineral that has been used in building materials and other products. The inhalation of asbestos fibers can lead to mesothelioma as well as other asbestos related diseases.

Get help with mesothelioma cancer – seek a mesothelioma lawyer who can assist with your financial situation.